Sargin G, et al. - Authors gauged the assocition between neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) ratio and disease activity in rheumatoid arthritis (RA) patients treated with rituximab. In patients with RA, the NLR and PLR were higher than healthy controls and associated with DAS28-ESR. They noted a decrease in these parameters which are indicative of disease activity with rituximab and these parameters correlate with disease activity at 6 months. Findings suggested probability of NLR and PLR to be useful to evaluate RA disease activity treated with rituximab.